Cellectar Biosciences, Inc. (CLRB): Price and Financial Metrics


Cellectar Biosciences, Inc. (CLRB): $0.44

0.04 (+9.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLRB Stock Price Chart Interactive Chart >

Price chart for CLRB

CLRB Price/Volume Stats

Current price $0.44 52-week high $1.84
Prev. close $0.40 52-week low $0.34
Day low $0.39 Volume 85,400
Day high $0.48 Avg. volume 191,701
50-day MA $0.55 Dividend yield N/A
200-day MA $0.70 Market Cap 26.88M

Cellectar Biosciences, Inc. (CLRB) Company Bio


Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is based in Madison, Wisconsin.


CLRB Latest News Stream


Event/Time News Detail
Loading, please wait...

CLRB Latest Social Stream


Loading social stream, please wait...

View Full CLRB Social Stream

Latest CLRB News From Around the Web

Below are the latest news stories about Cellectar Biosciences Inc that investors may wish to consider to help them evaluate CLRB as an investment opportunity.

Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?

Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

Yahoo | January 17, 2022

Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks

RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.

Yahoo | January 17, 2022

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Yahoo | January 14, 2022

Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference

FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced Jim Caruso, president and CEO and Jarrod Longcor, CBO, will participate in a fireside chat at the H.C. Wainwright Bioconnect conference taking place virtually January 10-13, 2022. The fireside chat will be available on demand begin

Yahoo | January 4, 2022

Cellectar Biosciences’ (CLRB) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Cellectar Biosciences (NASDAQ:CLRB) in a research report sent to investors on Monday, AnalystRatings.com reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. Separately, Zacks Investment Research cut Cellectar Biosciences from a buy rating to a hold rating in a research note on […]

Dakota Financial News | December 14, 2021

Read More 'CLRB' Stories Here

CLRB Price Returns

1-mo -14.61%
3-mo -8.31%
6-mo -36.43%
1-year -73.17%
3-year -81.36%
5-year -97.35%
YTD -33.73%
2021 -68.08%
2020 -7.56%
2019 45.16%
2018 -88.69%
2017 12.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7091 seconds.